Thanks tc... So this short interview basically det
Post# of 148291
(Total Views: 634)
Posted On: 05/18/2020 3:34:48 PM
Re: thriftycents #34430
Thanks tc... So this short interview basically detailed this morning's PR but there's some other news within it:
Dr. Jacob Lalezari:
Whether Remdesivir is an anti-viral as it claims remains "up in the air' ... have indication it reduces hospital stay from 15 to 11 days... want to see clear mortalitity benefits, time to discharge or return to good health.
Dr. Nader Pourhassan:
The UK is almost ready to be a site for us (trial site)... Mexico is close to being another site and of course a number of sites in the U.S.
Want to show Leronlimab is an immune corrective drug, not just for Covid-19 but for influenza and other indications (22 different cancers, HIV etc.).
All about correcting the immune system which can then handle all of these indications... we think results are going to be "very impressive."
Dr. Lalezari:
Follow up on safety... we know Remdesivir is a drug that can cause liver and kidney toxicity or problems (injury) so a lot of patients are not eligible to receive Rem... precisely because the disease itself (covid) is causing that organ dysfunction. We think inflamation is being driven by RANTES, the same immune chemical that's driving the entire illness of Covid-19 and is the "master switch" that we have been very fortunate with Leronlimab to shut down. After all the testing we have done with more than 800 HIV patients and with cancer and with covid-19 now, we can say there is no real serious adverse effect we can point to from Leronlimab.
Dr. Pourhassan:
Heard in the news Gilead will have 300K doses of Rem for patients this year. We have 1.2M to be delivered at the end of June or early July from Samsung Biologics alone and can ensure having more... two or three times that once we get good information from the FDA and what they think of our results.
When do you plan to submit this trial design?
Shooting for the end of this week or end of next week... we're working hard on all other avenues; we have so many other things we're doing right now.
He was happy with Dr. Patterson's two-hour presentation last night and explanation of how well Leron is working.
Unfortunately they were not asked about nor did they bring up who initiated doing any study/trial with Gilead (maybe not allowed to speak about it).
Dr. Jacob Lalezari:
Whether Remdesivir is an anti-viral as it claims remains "up in the air' ... have indication it reduces hospital stay from 15 to 11 days... want to see clear mortalitity benefits, time to discharge or return to good health.
Dr. Nader Pourhassan:
The UK is almost ready to be a site for us (trial site)... Mexico is close to being another site and of course a number of sites in the U.S.
Want to show Leronlimab is an immune corrective drug, not just for Covid-19 but for influenza and other indications (22 different cancers, HIV etc.).
All about correcting the immune system which can then handle all of these indications... we think results are going to be "very impressive."
Dr. Lalezari:
Follow up on safety... we know Remdesivir is a drug that can cause liver and kidney toxicity or problems (injury) so a lot of patients are not eligible to receive Rem... precisely because the disease itself (covid) is causing that organ dysfunction. We think inflamation is being driven by RANTES, the same immune chemical that's driving the entire illness of Covid-19 and is the "master switch" that we have been very fortunate with Leronlimab to shut down. After all the testing we have done with more than 800 HIV patients and with cancer and with covid-19 now, we can say there is no real serious adverse effect we can point to from Leronlimab.
Dr. Pourhassan:
Heard in the news Gilead will have 300K doses of Rem for patients this year. We have 1.2M to be delivered at the end of June or early July from Samsung Biologics alone and can ensure having more... two or three times that once we get good information from the FDA and what they think of our results.
When do you plan to submit this trial design?
Shooting for the end of this week or end of next week... we're working hard on all other avenues; we have so many other things we're doing right now.
He was happy with Dr. Patterson's two-hour presentation last night and explanation of how well Leron is working.
Unfortunately they were not asked about nor did they bring up who initiated doing any study/trial with Gilead (maybe not allowed to speak about it).
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼